» Articles » PMID: 32176738

Structural and Functional Insights into a Novel Two-component Endolysin Encoded by a Single Gene in Enterococcus Faecalis Phage

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2020 Mar 17
PMID 32176738
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Using bacteriophage-derived endolysins as an alternative strategy for fighting drug-resistant bacteria has recently been garnering renewed interest. However, their application is still hindered by their narrow spectra of activity. In our previous work, we demonstrated that the endolysin LysIME-EF1 possesses efficient bactericidal activity against multiple strains of Enterococcus faecalis (E. faecalis). Herein, we observed an 8 kDa fragment and hypothesized that it contributes to LysIME-EF1 lytic activity. To examine our hypothesis, we determined the structure of LysIME-EF1 at 1.75 Å resolution. LysIME-EF1 exhibits a unique architecture in which one full-length LysIME-EF1 forms a tetramer with three additional C-terminal cell-wall binding domains (CBDs) that correspond to the abovementioned 8 kDa fragment. Furthermore, we identified an internal ribosomal binding site (RBS) and alternative start codon within LysIME-EF1 gene, which are demonstrated to be responsible for the translation of the truncated CBD. To elucidate the molecular mechanism for the lytic activity of LysIME-EF1, we combined mutagenesis, lytic activity assays and in vivo animal infection experiments. The results confirmed that the additional LysIME-EF1 CBDs are important for LysIME-EF1 architecture and its lytic activity. To our knowledge, this is the first determined structure of multimeric endolysin encoded by a single gene in E. faecalis phages. As such, it may provide valuable insights into designing potent endolysins against the opportunistic pathogen E. faecalis.

Citing Articles

The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier.

Sabur A, Khan A, Borphukan B, Razzak A, Salimullah M, Khatun M J Xenobiot. 2025; 15(1).

PMID: 39997362 PMC: 11856723. DOI: 10.3390/jox15010019.


Structural and functional analysis reveals the catalytic mechanism and substrate binding mode of the broad-spectrum endolysin Ply2741.

Wang S, Li X, Ma J, Duan X, Wang H, Wang L Virulence. 2025; 16(1):2449025.

PMID: 39810299 PMC: 11740692. DOI: 10.1080/21505594.2024.2449025.


A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.

Wang S, Li X, Ji J, Li X, Zhu H, Duan X Front Microbiol. 2024; 15:1482189.

PMID: 39493846 PMC: 11527626. DOI: 10.3389/fmicb.2024.1482189.


Identification of cell wall binding domains and repeats in phage endolysins: A molecular and diversity analysis.

Khan T, Mondal S, Mahmud A, Karim D, Draper L, Hill C Biochem Biophys Rep. 2024; 40:101844.

PMID: 39483175 PMC: 11525621. DOI: 10.1016/j.bbrep.2024.101844.


Mechanistic basis for the allosteric activation of NADase activity in the Sir2-HerA antiphage defense system.

Zhen X, Zhou B, Liu Z, Wang X, Zhao H, Wu S Nat Commun. 2024; 15(1):9269.

PMID: 39465277 PMC: 11514289. DOI: 10.1038/s41467-024-53614-6.


References
1.
Yang H, Gong Y, Zhang H, Etobayeva I, Miernikiewicz P, Luo D . ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain. Antimicrob Agents Chemother. 2019; 63(4). PMC: 6437478. DOI: 10.1128/AAC.02043-18. View

2.
Schuck P . Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J. 2000; 78(3):1606-19. PMC: 1300758. DOI: 10.1016/S0006-3495(00)76713-0. View

3.
Gutierrez D, Fernandez L, Rodriguez A, Garcia P . Are Phage Lytic Proteins the Secret Weapon To Kill ?. mBio. 2018; 9(1). PMC: 5784253. DOI: 10.1128/mBio.01923-17. View

4.
Lin D, Koskella B, Lin H . Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017; 8(3):162-173. PMC: 5547374. DOI: 10.4292/wjgpt.v8.i3.162. View

5.
Fischetti V . Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. Viruses. 2018; 10(6). PMC: 6024357. DOI: 10.3390/v10060310. View